Ball Appointed to Enliven Therapeutics Board Amid Phase 3 Trial Prep
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kristine Ball was appointed to the board of directors of Enliven Therapeutics, Inc. on October 14, 2026. Ball brings over 20 years of executive experience from clinical-stage and commercial-stage biopharmaceutical companies.
From prnewswire.com
Why it matters
The appointment comes as Enliven Therapeutics prepares to initiate a pivotal Phase 3 trial of relcobatinib before the end of the year and plans for commercialization. Ball's background in transitioning companies from clinical development to commercial operations is noted as valuable for the company's strategy.
From prnewswire.com
Who's involved
- BallNew member of the board of directors
- board of directorsGoverning body of Enliven Therapeutics, Inc.
Keep exploring
The entities involved
-
Ball
Taiwanese progamer
-
board of directors
group of people who jointly supervise the activities of an organization